Article ; Online: Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study.
2023 Volume 23, Issue 3, Page(s) 287–296
Abstract: Background: Cardiac adverse events (AEs) are common in tyrosine kinase inhibitors(TKIs). This study explored the cardiac AEs of TKIs through the Food and Drug Administration's Adverse Event Reporting System (FAERS).: Methods: Disproportionality ... ...
| Abstract | Background: Cardiac adverse events (AEs) are common in tyrosine kinase inhibitors(TKIs). This study explored the cardiac AEs of TKIs through the Food and Drug Administration's Adverse Event Reporting System (FAERS). Methods: Disproportionality analysis and Bayesian analysis were utilized for data mining of the suspected cardiac AEs of TKIs, based on FAERS data from January 2004 to December 2021. Results: A total of 4708 cardiac AEs reports of sorafenib, regorafenib, lenvatinib, and cabozantinib were identified. Hypertension accounts for the most reported cardiac AE. Lenvatinib appears to induce cardiac failure with the highest signals strength [ROR = 7.7 (3.46,17.17)]. Acute myocardial infarction was detected in lenvatinib [ROR = 7.91 (5.64,11.09)] and sorafenib [ROR = 2.22 (1.74, 2.84)]. Acute coronary syndrome was detected in lenvatinib [ROR = 11.57 (6.84, 19.58)] and sorafenib [ROR = 2.81 (1.87,4.24)]. Atrial fibrillation was detected in sorafenib [ROR = 1.82 (1.55,2.14)] and regorafenib [ROR = 1.36 (1.03,1.81)]. Meanwhile, aortic dissections were detected in sorafenib [ROR = 5.08 (3.31,7.8)] and regorafenib [ROR = 3.39 (1.52,7.56)]. Most patients developed hypertension and cardiac failure within 30 days of initiating TKI treatments. Patients taking lenvatinib had an increased incidence of developing acute coronary syndrome after 180 days of treatment. Conclusion: Analysis of FAERS data provides a precise profile on the characteristics of cardiac AEs associated with different TKI regimens. Distinct monitoring and appropriate management are needed in the care of TKI recipients. |
|---|---|
| MeSH term(s) | United States ; Humans ; Tyrosine Kinase Inhibitors ; Acute Coronary Syndrome ; Sorafenib/adverse effects ; Retrospective Studies ; Bayes Theorem ; Carcinoma, Hepatocellular/drug therapy ; Pharmacovigilance ; Liver Neoplasms/drug therapy ; Heart Failure ; Hypertension ; United States Food and Drug Administration ; Adverse Drug Reaction Reporting Systems ; Phenylurea Compounds ; Pyridines ; Quinolines |
| Chemical Substances | regorafenib (24T2A1DOYB) ; lenvatinib (EE083865G2) ; Tyrosine Kinase Inhibitors ; Sorafenib (9ZOQ3TZI87) ; Phenylurea Compounds ; Pyridines ; Quinolines |
| Language | English |
| Publishing date | 2023-08-29 |
| Publishing country | England |
| Document type | Journal Article |
| ZDB-ID | 2088728-0 |
| ISSN | 1744-764X ; 1474-0338 |
| ISSN (online) | 1744-764X |
| ISSN | 1474-0338 |
| DOI | 10.1080/14740338.2023.2251398 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6096: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.